Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Microbot Medical Q3 2026 Results: Net Loss of $5.84M, Loss Widens

Microbot Medical Inc. reported a net loss of $15.14 million for the nine months ended September 30, 2026, compared to $9.68 million in the prior year, as the company began generating initial revenues of $418,000. Operating expenses increased significantly, particularly in sales and marketing, while cash and marketable securities decreased to approximately $61.8 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.1—
Gross profit-1.0—
Net income-5.8-3.6
EPS (diluted, $ a share)$-0.09$-0.07

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MBOT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Microbot Medical Inc.: key numbers

Share price
$0.6444Close, Nov 16
Market cap
$43.3M
Shares outstanding
67.16MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Microbot Medical Inc.

All →
8:32 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical provided a third quarter 2026 operational update highlighting a 44% sequential increase in procedure utilization for its LIBERTY Endovascular Robotic System. The company ended the quarter with $62 million in cash and expanded its commercial footprint to 12 customer accounts and 10 sales territories.

8:32 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical announced that the Canadian Intellectual Property Office granted a patent for an adaptor used in its LIBERTY Endovascular Robotic System. This grant brings the company's global intellectual property portfolio to 45 issued patents and 48 pending applications, supporting its strategy for international commercialization expansion.

Counterparty
Canadian Intellectual Property Office
8:31 AM ET 8-K
Contract Win

Microbot Medical Wins Contract from Elmnt Ir

Microbot Medical secured its first Office-Based Laboratory (OBL) customer, ELMNT IR, which signed an order for up to a 12-month supply of the LIBERTY Endovascular Robotic System. This marks the company's first customer on the U.S. West Coast and supports its strategy to expand into outpatient interventional radiology settings.

Counterparty
ELMNT IR
Term
12 months
8:31 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical announced its attendance at the SIR EDGE 2026 conference and the ACIR Annual Fall Conference to engage with interventional radiologists and hospital administrators. The company aims to leverage these events to generate sales leads and foster adoption of its FDA-cleared LIBERTY Endovascular Robotic System as it expands its U.S. commercial footprint.

8:31 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical announced it has received several new patent approvals for its LIBERTY Endovascular Robotic System in the U.S., Japan, China, and Canada. The company's global intellectual property portfolio now includes 44 issued patents and 49 pending applications as it pursues commercial expansion and a CE Mark for international markets.

8:30 AM ET 8-K
Contract Win

Microbot Medical Wins Contract from Medtechnica Ltd.

Microbot Medical Inc. entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System in Israel. The company expects initial orders under the agreement to begin in the fourth quarter of 2026 following prior regulatory approval from the Israeli Ministry of Health.

Counterparty
Medtechnica Ltd.
Term
3 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.